-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：嘉信理財（Charles Schwab Corporation，股票代號：SCHW）第一季每股收益為1.43美元，高於市場普遍預期的1.39美元及去年同期的1.04美元，季淨收入達64.8億美元（年成長16%），創公司歷史新高。收入成長全面，淨利息收入成長16%，資產管理和行政費用成長15%，交易收入成長20%。我們認為，這些業績表明，在市場不確定性加劇的情況下，嘉信理財多元化的商業模式仍然強勁。資產成長動能良好，第一季新增經紀帳戶130萬個，核心淨新增資產達1,400億美元。客戶參與度也創下歷史新高，日均交易量達到990萬筆（年增34%），客戶總資產達11.77兆美元（年成長19%）。由於收益率上升和融資狀況改善，淨利差從上年的2.53%擴大至2.88%。該公司雄厚的資本實力使其得以回購24億美元的股票，並將股利提高19%至每股0.32美元。我們相信，SCHW多元化的商業模式和不斷深化的客戶關係將支撐其持續成長。
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF